Clinical Study to Evaluate Different Energy-based Devices for Aesthetic Treatments.

Not Applicable

Recruiting

• Conditions: Dermatologic Conditions
• Interventions: Device: Intense pulsed light.; Device: Radiofrequency microneedling device; Device: Radiofrequency device; Device: Combined energy devices

• Registration Number: NCT06111482
• Lead Sponsor: Cynosure, Inc.

Brief Summary

The goal of the energy-based devices used in this study is to evaluate their safety and performance to treat unwanted dermatologic conditions.

Detailed Description

Up to 50 subjects will be enrolled at 1 study center. Subjects will be enrolled into 4 groups: Group A, Group B, Group C, or Group D. Subjects may enroll in more than one group, however the last treatment in the previous group would be at least 30 days before the subject is enroll in the next group if treatment area is the same.

Study Timeline

• Study Start: 2023-09-28
• Status Verified: 2023-10
• Study First Submitted: 2023-10-20
• Study First Submitted QC: 2023-10-26
• Last Update Submitted: 2023-10-26
• Study First Posted: 2023-11-01
• Last Update Posted: 2023-11-01
• Primary Completion: 2025-02
• Study Completion: 2025-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• A healthy male or female 22 years of age or older.
• Willing to undergo at least 1 treatment with the study device(s).
• Understands and accepts obligation not to receive any other procedures in the treatment area through the length of the study.
• Understands and accepts the obligation and is logistically able to be present for all visits.
• Is willing to comply with all requirements of the study and sign the informed consent document

Exclusion Criteria

• Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
• Takes or has taken oral isotretinoin, such as Accutane®, within the last six months.
• Is using systemic steroids (e.g., prednisone, dexamethasone) prior to or during the course of treatment.
• Is receiving or has received gold therapy.
• Is taking medications that alter the wound-healing response or has a history of healing problems.
• Has an active localized or systemic infection, or an open wound in area being treated.
• Has a significant systemic illness, such as lupus, or an illness localized in area being treated.
• Has a seizure disorders triggered by light.
• Has a history of skin photosensitivity disorders.
• Has a history of hypertrophic scars or keloid formation.
• Has a history of radiation therapy in area to be treated.
• Received fillers or neurotoxin injections in the treatment area within the past 2 weeks.
• Has had a chemical or mechanical epilation within the last six weeks.
• Currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months to entering this study.
• Has any condition or is in a situation which in the investigator's opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Radiofrequency Device Only:

• Has a Pacemaker
• Has any embedded electronic devices that give or receive a signal.
• Has electronic implants, such as Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant.
• Is allergic to adhesives such as glues on medical tape: they should be alerted that a rash may occur on the neutral electronic monitoring pad (NEM or neutral pad) site, and an over-the-counter preparation may be used to treat the area.
• Has nerve insensitivity to heat in the treatment area or in the neutral pad placement area.
• Is allergic to topical anesthetic

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Combination	Intense pulsed light.	Group D will receive combination treatments and will be treated with 2 or more of the study devices.
RF Microneedling Only	Radiofrequency microneedling device	Group B will be treated with a radiofrequency (RF) microneedling device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF microneedling device that is cleared for use by the FDA.
RF Only	Radiofrequency device	Group C will be treated with an RF device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF device that is cleared for use by the FDA.
IPL only	Intense pulsed light.	Group A will be treated with an intense pulsed light (IPL) device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar IPL device that is cleared for use by the FDA.
Combination	Combined energy devices	Group D will receive combination treatments and will be treated with 2 or more of the study devices.
Combination	Radiofrequency microneedling device	Group D will receive combination treatments and will be treated with 2 or more of the study devices.
Combination	Radiofrequency device	Group D will receive combination treatments and will be treated with 2 or more of the study devices.

Primary Outcome Measures

Name	Time	Method
Maximum pain reported during treatment.	procedure (during device treatment)]	The maximum pain during treatment per each device will be reported on a scale of 0(none) to 10 (maximum intolerable pain). This pain is recorded during when the patient is actively treated (when the patient comes in and receives a treatment from the device).

Trial Locations

Locations (1)

Cynosure; 🇺🇸 Westford, Massachusetts, United States